Published in

BMJ Publishing Group, Archives of Disease in Childhood, 7(100), p. 682-683, 2015

DOI: 10.1136/archdischild-2014-307906

Links

Tools

Export citation

Search in Google Scholar

When to report adverse drug reactions in children?

Journal article published in 2015 by Christopher Barton, Daniel B. Hawcutt ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The use of medicines can never be 100% safe, or 100% effective, and therefore each prescription is a balance of the intended benefits from using the medication versus the risks associated with it. Any patient using medicines may experience only the positive effects, only the negative effects, a combination of both positive and negative effects or no effects at all. The negative effects of medicines are referred to as ‘adverse drug reactions’ (ADRs) and are officially defined as ‘A response to a medicinal product which is noxious and unintended’.1 A negative symptom or effect of a medicine may be categorised as an ADR regardless of how a drug has been used, and so includes abuse, overdose, industrial exposure, medication errors, and unlicensed and/or off-label use. To generate data on ADRs, including identification of previously unsuspected ADRs, the UK set up one of the world's first spontaneous reporting schemes for collecting SUSPECTED ADRs in 1964. These data were initially collected by doctors who would complete a yellow-coloured card found at the back of the British National Formulary (BNF). Fifty years later, although the range of potential reporters and means of completion have evolved, the ‘Yellow Card’ Scheme continues to be a vitally important mechanism to collect these data. To identify the rarest ADRs, national data may not be sufficient, and so the WHO Programme for International Drug Monitoring was established in 1968 and has been coordinated by the Uppsala Monitoring Centre (UMC) in Sweden since 1978. The UMC is a WHO collaborating centre currently collecting, … [Full text of this article]